Click on the links below to access the Industry Sponsored Satellite Symposia Invitations.
Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer
A New Decade in the Evolving Treatment Landscape for HER2 Positive Metastatic Breast Cancer
Debate: In the Modern Management of HER2-HR+MBC, Should Chemotherapy be the Treatment of Last Resort?
The Power of Choice in HR+, HER2- Advanced Breast Cancer: A Case Continuum
The Evolving Treatment Landscape of Early Triple Negative Breast Cancer
Optimising Breast Cancer Outcomes: Clinical and Real-World Experience Lead to Strength in numbers
How to do More to Improve HER2-positive Early Breast Cancer Patient Outcomes?
Improving Outcomes After T-DM1: A New Horizon for HER2+ mBC Patients
Bringing Molecular Insights to The Clinic: Recent Advances in Breast Cancer Treatment
Please note: The European Society for Medical Oncology (ESMO) does not endorse any of the companies, or their products/services, that have sponsored these links.